Serum Magnesium Levels in Desalination Tap Water and Outcomes in Acute Myocardial Infarction Patients

Completed

• Conditions: Death; Cardiovascular Disease; Myocardial Infarction; Congestive Heart Failure; Acute-MI

• Registration Number: NCT02356393
• Lead Sponsor: Sheba Medical Center

Brief Summary

Association between serum magnesium and clinical outcome in patients with acute MI (AMI) with 1 year follow-up in 300 patients in regions supplied by desalinated drinking water (DSW) (Sheba MC) and 150 patients in regions with non-desalinated drinking water (DW) (Nahariya MC).

Detailed Description

Extensive seawater desalination in Israel may decrease magnesium in drinking water (DW), causing hypomagnesemia and adverse health effects. We study the association between consumption of desalinated drinking water (DSW) and serum magnesium in acute MI (AMI) patients, Subjects 35-75 years of age with the first AMI will be prospectively recruited during 1 year from 2 regions; the Departments of Cardiology at the Sheba Medical center (300 patients, predominantly served by DSW) and the Nahariya Medical Center (150 patients, served by non-DSW). Questionnaire will be developed to collect data on demographic variables (at home and work), water and beverages consumption habits (tap water, mineral water), dietary sources of Mg and Mg supplementations. Mg levels will be measured in DW from the patients' homes and in their serum on admission.

Study Timeline

• Study First Submitted: 2014-12-04
• Study First Submitted QC: 2015-02-01
• Study First Posted: 2015-02-05
• Study Start: 2015-05
• Status Verified: 2023-12
• Primary Completion: 2023-12-01
• Study Completion: 2023-12-01
• Last Update Submitted: 2023-12-10
• Last Update Posted: 2023-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Patients with first AMI
2. Age 35-75

Exclusion Criteria

1. Patients > age 75

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of Major Adverse Cardiovascular Events (MACE)	1 year	MACE including: acute infarct returns, revascularization, death within 30 days or one year, hospitalization for heart failure, hospitalization for angina pectoris and transient ischemic events.

Secondary Outcome Measures

Name	Time	Method
Age	1 year	Age at the first Acute Myocardial Infraction

Trial Locations

Locations (1)

Leviev Heart Center, Chaim Sheba Medical Center; 🇮🇱 Ramat Gan, Israel